Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.
about
Manufacturing of recombinant adeno-associated viral vectors for clinical trialsAdeno-associated virus: a key to the human genome?The status of exon skipping as a therapeutic approach to duchenne muscular dystrophyGood manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trialSystemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverLarge-scale recombinant adeno-associated virus productionGenetic therapies for cystic fibrosis lung diseaseReproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures.Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challengesLong-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skippingRecombinant adeno-associated viral vector production and purification.Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaquesProgress and challenges in viral vector manufacturingBaculovirus: an insect-derived vector for diverse gene transfer applicationsA concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapyOneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapyRecombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo.Peptide affinity reagents for AAV capsid recognition and purificationThe baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography.The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system.A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.Targeting transgene to the heart and liver with AAV9 by different promoters.AAV9: over the fence and into the woods . . .Advancements in the design and scalable production of viral gene transfer vectors.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale.Capsid protein expression and adeno-associated virus like particles assembly in Saccharomyces cerevisiae.Pharmacology of Recombinant Adeno-associated Virus Production.
P2860
Q26750799-015909DB-939A-4AB2-8977-78EB8DEBC6EEQ34459999-0D4B2D10-AEBB-46FA-96C5-519EA3AB4391Q34473336-6A37A655-6F3E-4694-8D81-8894F74C339FQ34843808-7E8B9BBA-01DF-4316-8AFE-4C78007B3F56Q34843835-9A571FFD-7BFF-41C8-B693-B77EE4167B0BQ34982857-E9CCFBFE-71E5-4D16-9AF5-AFFF9C2B741BQ34982862-0203997E-5AE3-4608-9778-E853822A4323Q35174927-F8FB56BD-C0B8-410B-985F-D4BD8189E64FQ35431994-3DD662D0-FDBA-4353-8C2A-757C82608D54Q35802092-6134ABF3-AFDF-4B55-968F-A3981E206AD0Q35819157-3B6277DE-FF99-4DCB-9F12-2C8A40347BABQ36114234-52C0B1BE-3DD6-4002-9A27-D2A5AF0D6F13Q36713761-8657C7B7-1FCA-40B0-8D70-D865A7495B21Q36740261-1A4B0478-CABD-48FC-A17E-D302EBC3293BQ37012949-4371DB36-18CD-40E4-8095-9CDA7572ADDEQ37640503-FCE1D875-8067-40CB-B13F-B3A10EBC4C16Q37720225-F564FA42-D7BD-4C9E-BC68-2F484D3FB34EQ38335916-B8A50B11-5F6B-412B-963A-DC854DFB7FD0Q38388047-2E5D44D0-BD35-4658-921F-25CF6021BEF4Q39407680-F39D6669-00B0-4E36-BF8F-3FA1B1873606Q39669977-FE1D5376-E903-40C3-9D91-E1A10BF34C43Q39674124-E2607462-7B96-4F9A-9E88-76B62AD08B51Q39737661-062537AD-F94F-4E3B-A3E1-49DFC4B76C90Q40738027-F868DB22-21F2-4085-A2FA-286CDADA76C5Q41880721-67E48ACC-F1B3-4D22-82CD-8B21653BB523Q41931475-A1934C22-69C4-4821-A52C-EC81CF6EC284Q42408230-AD8DE72A-19C2-41ED-890B-633F014DCD45Q42574850-6D278885-6D57-4386-9B98-2AAD3E20DB1AQ52717185-9C41DCD9-C8FA-4CC4-BF07-CC48B72304D7
P2860
Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Producing recombinant adeno-as ...... sect cell expression strategy.
@ast
Producing recombinant adeno-as ...... sect cell expression strategy.
@en
type
label
Producing recombinant adeno-as ...... sect cell expression strategy.
@ast
Producing recombinant adeno-as ...... sect cell expression strategy.
@en
prefLabel
Producing recombinant adeno-as ...... sect cell expression strategy.
@ast
Producing recombinant adeno-as ...... sect cell expression strategy.
@en
P2093
P2860
P356
P1433
P1476
Producing recombinant adeno-as ...... sect cell expression strategy.
@en
P2093
Robert M Kotin
Sylvain Cecchini
Tamas Virag
P2860
P304
P356
10.1089/HUM.2009.092
P577
2009-08-01T00:00:00Z